» Articles » PMID: 25617365

Inositol Pyrophosphates Promote Tumor Growth and Metastasis by Antagonizing Liver Kinase B1

Overview
Specialty Science
Date 2015 Jan 25
PMID 25617365
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The inositol pyrophosphates, molecular messengers containing an energetic pyrophosphate bond, impact a wide range of biologic processes. They are generated primarily by a family of three inositol hexakisphosphate kinases (IP6Ks), the principal product of which is diphosphoinositol pentakisphosphate (IP7). We report that IP6K2, via IP7 synthesis, is a major mediator of cancer cell migration and tumor metastasis in cell culture and in intact mice. IP6K2 acts by enhancing cell-matrix adhesion and decreasing cell-cell adhesion. This action is mediated by IP7-elicited nuclear sequestration and inactivation of the tumor suppressor liver kinase B1 (LKB1). Accordingly, inhibitors of IP6K2 offer promise in cancer therapy.

Citing Articles

Insights into targeting LKB1 in tumorigenesis.

Trelford C, Shepherd T Genes Dis. 2024; 12(2):101402.

PMID: 39735555 PMC: 11681833. DOI: 10.1016/j.gendis.2024.101402.


Genetic Deletion of Skeletal Muscle Inositol Polyphosphate Multikinase Disrupts Glucose Homeostasis and Impairs Exercise Tolerance.

Lee J, Jung I, Tu-Sekine B, Jin S, Anokye-Danso F, Ahima R bioRxiv. 2024; .

PMID: 39131310 PMC: 11312436. DOI: 10.1101/2024.07.28.605526.


Insights into the roles of inositol hexakisphosphate kinase 1 (IP6K1) in mammalian cellular processes.

Chakkour M, Greenberg M J Biol Chem. 2024; 300(4):107116.

PMID: 38403246 PMC: 11065760. DOI: 10.1016/j.jbc.2024.107116.


Shaping the Future of Obesity Treatment: In Silico Multi-Modeling of IP6K1 Inhibitors for Obesity and Metabolic Dysfunction.

Mondal I, Halder A, Pattanayak N, Mandal S, Cordeiro M Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399478 PMC: 10891520. DOI: 10.3390/ph17020263.


Kcs1 and Vip1: The Key Enzymes behind Inositol Pyrophosphate Signaling in .

Gogianu L, Ruta L, Farcasanu I Biomolecules. 2024; 14(2).

PMID: 38397389 PMC: 10886477. DOI: 10.3390/biom14020152.


References
1.
Saiardi A, Nagata E, Luo H, Snowman A, Snyder S . Identification and characterization of a novel inositol hexakisphosphate kinase. J Biol Chem. 2001; 276(42):39179-85. DOI: 10.1074/jbc.M106842200. View

2.
Aoki M, Sobek V, Maslyar D, Hecht A, Vogt P . Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene. 2002; 21(46):6983-91. DOI: 10.1038/sj.onc.1205796. View

3.
Ewan K, Henshall-Powell R, Ravani S, Pajares M, Arteaga C, Warters R . Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res. 2002; 62(20):5627-31. View

4.
Baas A, Boudeau J, Sapkota G, Smit L, Medema R, Morrice N . Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 2003; 22(12):3062-72. PMC: 162144. DOI: 10.1093/emboj/cdg292. View

5.
Lizcano J, Goransson O, Toth R, Deak M, Morrice N, Boudeau J . LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004; 23(4):833-43. PMC: 381014. DOI: 10.1038/sj.emboj.7600110. View